Dupilumab Reduces Biomarkers Indicative of Type 2 Inflammation in Children Aged ≥ 6 Months to < 6 YearsWith Moderate-to-Severe Atopic Dermatitis

被引：0

作者：

Pinter, Andreas ^{[1
]}

Paller, Amy ^{[2
,3
]}

Guttman-Yassky, Emma ^{[4
,5
]}

Boguniewicz, Mark ^{[6
,7
]}

Sun, Yiping ^{[8
]}

Wolfe, Kelley ^{[9
]}

Dillon, Myles ^{[8
]}

机构：

[1] Univ Hosp Frankfurt Main, Frankfurt, Germany

[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

[3] Ann & Robert H Lurie Childrens Hosp, Chicago, IL USA

[4] Icahn Sch Med Mt Sinai, Med Ctr, New York, NY USA

[5] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA

[6] Natl Jewish Hlth, Denver, CO USA

[7] Univ Colorado, Sch Med, Denver, CO USA

[8] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[9] Sanofi, Bridgewater, MA USA

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P155

引用

页码：100 / 100

页数：1

共 50 条

[31] Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis
Silverberg, Jonathan, I
Rubini, Norma P. M.
Pires, Mario C.
Rossi, Ana B.
Zhang, Annie
Chen, Zhen
Levit, Noah A.
Chao, Jingdong
Shumel, Brad
Bego-Le Bagousse, Gaelle
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (05): : 1279 - +
[32] Dupilumab treatment normalizes skin barrier function in children aged 6-11 years with moderate-to-severe atopic dermatitis
Cork, Michael J.
Leung, Donald
Ong, Peck
Danby, Simon
Ramirez-Gama, Marco
Garcia, Shannon
Patricia, Taylor
Byers, Rob
Matcher, Stephen
Zahn, Joseph
Bologna, Gabriel
Zhang, Annie
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I30 - I30
[33] Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children
Parker, Jennifer J.
Sugarman, Jeffrey L.
Silverberg, Nanette B.
Gonzalez, Mercedes Elena
Ramien, Michele L.
Teng, Joyce M. C.
Paller, Amy S.
PEDIATRIC DERMATOLOGY, 2021, 38 (06) : 1500 - 1505
[34] Dupilumab treatment in children with moderate-to-severe atopic dermatitis increases levels of bone mineralization biomarkers
Irvine, A. D.
Paller, A.
Horowitz, J. E.
Farrell, A.
Hatsell, S.
Ehmann, P.
Rodriguez Marco, A.
Tian, T.
Cyr, S. L.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S110 - S110
[35] Dupilumab treatment in children with moderate-to-severe atopic dermatitis increases levels of bone mineralization biomarkers
Irvine, Alan D.
Paller, Amy S.
Horowitz, Julie E.
Farrell, Annamaria
Hatsell, Sarah
Ehmann, Peter
McDonald, Robert
Marco, Ainara Rodriguez
Tian, Tingting
Cyr, Sonya L.
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[36] Dupilumab treatment normalizes skin barrier function and symptoms in children aged 6-11 years with moderate-to-severe atopic dermatitis
Leung, D. Y.
Cork, M. J.
Ong, P.
Danby, S.
Ramirez-Gama, M.
Garcia, S.
Taylor, P.
Zahn, J.
Bologna, G.
Zhang, A.
ALLERGY, 2023, 78 : 194 - 194
[37] Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Paller, Amy S.
Siegfried, Elaine C.
Cork, Michael J.
Wollenberg, Andreas
Arkwright, Peter D.
Gonzalez, Mercedes E.
Lockshin, Benjamin
Chen, Zhen
Bansal, Ashish
Levit, Noah A.
Prescilla, Randy
PEDIATRIC DRUGS, 2023, 25 (01) : 67 - 77
[38] Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Amy S. Paller
Elaine C. Siegfried
Michael J. Cork
Andreas Wollenberg
Peter D. Arkwright
Mercedes E. Gonzalez
Benjamin Lockshin
Zhen Chen
Ashish Bansal
Noah A. Levit
Randy Prescilla
Pediatric Drugs, 2023, 25 : 67 - 77
[39] Efficacy and safety of dupilumab in children aged 6 months to 5 years with atopic dermatitis with and without type 2 comorbidities
Boguniewicz, M.
Sher, L.
Paller, A. S.
Chen, Z.
Shah, P.
Marco, A. Rodriguez
ALLERGY, 2023, 78
[40] Dupilumab Efficacy in Children With Atopic Dermatitis Aged 6 Months to 5 Years With and Without Atopic Comorbidities
Boguniewicz, Mark
Sher, Lawrence
Paller, Amy
Chen, Zhen
Shah, Parul
Rodriguez-Marco, Ainara
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB148 - AB148

← 1 2 3 4 5 →

Dupilumab Reduces Biomarkers Indicative of Type 2 Inflammation in Children Aged ≥ 6 Months to &lt; 6 YearsWith Moderate-to-Severe Atopic Dermatitis

Dupilumab Reduces Biomarkers Indicative of Type 2 Inflammation in Children Aged ≥ 6 Months to < 6 YearsWith Moderate-to-Severe Atopic Dermatitis